2026 Q2 - tulosraportti
56 päivää sitten
‧33 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 12.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 13.8.2025 |
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·11.9.Key points of the news Classification as Class III Medical Device: The approval applies to their ProSense cryoablation technology (and associated probes). Class III is the strictest category in China for devices used for life-sustaining or invasive procedures. What does the technology do? ProSense uses extreme cold (liquid nitrogen) to freeze and destroy tumors (both benign and cancerous) in e.g., breast, kidneys, lungs, and bones as a gentle alternative to traditional surgery. Opening up a giant market: China is an enormous market with hundreds of thousands of new cancer cases annually, and the approval officially opens the doors for the company to commercialize and sell their systems there (often via local distribution agreements, including with strong partners like Medtronic's local branches). Is it good or bad? This is clearly very good news for IceCure Medical for several reasons: Access to a massive market: China is one of the world's largest growth markets for health technology. Getting through the eye of the needle that the Chinese NMPA approval represents opens up enormous sales potential in the long term. Validation of the technology: Passing the eye of the needle to get a Class III approval serves as a seal of quality for the product's safety and effectiveness, which also strengthens the company's global position. Strained company needs growth: Like many other small biotech companies, IceCure has historically struggled with weak earnings and low stock prices. News of commercial expansion of this caliber is precisely the type of catalyst investors look for to boost revenue. All in all, a strategic feather in the cap for IceCure, moving them from pure development and approval phase into a real, global sales phase in one of the world's most important markets. https://finance.yahoo.com/healthcare/articles/icecure-secures-china-nmpa-approval-135700845.html- ·14.7. · Muokattuhttps://finance.yahoo.com/healthcare/articles/icecure-expands-u-commercial-team-123200784.html The company has just announced a significant expansion of their US sales and marketing team. This comes as a direct response to an explosively growing demand for their flagship product, the ProSense® system, for the treatment of early-stage breast cancer. What is the background for the news? 70% growth in the USA: IceCure recently announced that their active commercial installed base in the USA has grown by a full 70%. This growth was triggered by them receiving crucial FDA approval in October 2025 to treat low-risk, early-stage breast cancer in women over 70 years old. Geographical expansion: To meet demand, the company has hired dedicated sales and marketing staff in key regions such as New York, Southern California, and the Midwest. ProSense procedures are now performed in major metropolitan areas like Los Angeles, Detroit, Dallas, and Atlanta. What does this mean for you as an investor? If you look at IceCure through investor glasses, there are three crucial things to take away from this expansion: 1. The company shifts gears from "development" to "commercial execution" For many years, IceCure has been a case about clinical studies (such as the large ICE-3 study) and waiting for FDA. Now the approval is in, and the company shows action by building the sales infrastructure needed to convert clinical success into hard dollars. 2. The "Razor and Blade" model begins to roll: IceCure operates on a business model where they sell both the machine (ProSense) and the disposable needles (probes) used for every freeze treatment. More salespeople in the field -> More installed machines -> A rapidly increasing and recurring sale of disposable needles with high margins. 3. The Risk: Increased "Burn Rate" in the short term When expanding its sales team, the company's operating costs (SG&A) immediately increase, while revenues from increased sales typically lag a bit (because the sales cycle in hospitals can take 3-9 months). As an investor, you should keep an eye on their cash reserves (they had approx. 8.1 million USD in cash at the end of Q1 2026) to ensure they have enough money to finance this growth phase without further diluting shareholders in the near future. Overall assessment: This is a classic "growth news". It confirms that there is real, organic demand in the US market for an alternative to traditional breast surgery (lumpectomy). It costs money to make money, and IceCure is now stepping on the gas in the USA to quickly gain market share. 🤞🤝
·25.6.Most things seem to point in the right direction, competent management, great potential for the product, analysts who are unequivocally positive and high price targets. These are shares at a cheap price now. There is also a high probability that the application in Japan will go through, as Terumo is responsible for the application.- ·25.6. · MuokattuWhy is this important for IceCure? Retains large investors: Many investment funds and institutional investors have rules that they are not allowed to own shares that cost under 1 dollar, or shares that are traded on the unregulated "penny stock" markets. By remaining on Nasdaq, IceCure maintains access to the big money. Peace of mind: Management has now averted a potential crisis. Instead of having to spend energy on panic solutions (such as a reverse stock split, where shares are merged to artificially pump up the price), they can now focus 100% on their business – such as the upcoming approval process in Japan, which you read about in the other news. Sign of confidence: That the share price has climbed back above 1 dollar by its own strength often shows that the market and investors have gained greater faith in the company's future, potentially aided by good clinical news. Important! 🙏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
56 päivää sitten
‧33 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·11.9.Key points of the news Classification as Class III Medical Device: The approval applies to their ProSense cryoablation technology (and associated probes). Class III is the strictest category in China for devices used for life-sustaining or invasive procedures. What does the technology do? ProSense uses extreme cold (liquid nitrogen) to freeze and destroy tumors (both benign and cancerous) in e.g., breast, kidneys, lungs, and bones as a gentle alternative to traditional surgery. Opening up a giant market: China is an enormous market with hundreds of thousands of new cancer cases annually, and the approval officially opens the doors for the company to commercialize and sell their systems there (often via local distribution agreements, including with strong partners like Medtronic's local branches). Is it good or bad? This is clearly very good news for IceCure Medical for several reasons: Access to a massive market: China is one of the world's largest growth markets for health technology. Getting through the eye of the needle that the Chinese NMPA approval represents opens up enormous sales potential in the long term. Validation of the technology: Passing the eye of the needle to get a Class III approval serves as a seal of quality for the product's safety and effectiveness, which also strengthens the company's global position. Strained company needs growth: Like many other small biotech companies, IceCure has historically struggled with weak earnings and low stock prices. News of commercial expansion of this caliber is precisely the type of catalyst investors look for to boost revenue. All in all, a strategic feather in the cap for IceCure, moving them from pure development and approval phase into a real, global sales phase in one of the world's most important markets. https://finance.yahoo.com/healthcare/articles/icecure-secures-china-nmpa-approval-135700845.html
- ·14.7. · Muokattuhttps://finance.yahoo.com/healthcare/articles/icecure-expands-u-commercial-team-123200784.html The company has just announced a significant expansion of their US sales and marketing team. This comes as a direct response to an explosively growing demand for their flagship product, the ProSense® system, for the treatment of early-stage breast cancer. What is the background for the news? 70% growth in the USA: IceCure recently announced that their active commercial installed base in the USA has grown by a full 70%. This growth was triggered by them receiving crucial FDA approval in October 2025 to treat low-risk, early-stage breast cancer in women over 70 years old. Geographical expansion: To meet demand, the company has hired dedicated sales and marketing staff in key regions such as New York, Southern California, and the Midwest. ProSense procedures are now performed in major metropolitan areas like Los Angeles, Detroit, Dallas, and Atlanta. What does this mean for you as an investor? If you look at IceCure through investor glasses, there are three crucial things to take away from this expansion: 1. The company shifts gears from "development" to "commercial execution" For many years, IceCure has been a case about clinical studies (such as the large ICE-3 study) and waiting for FDA. Now the approval is in, and the company shows action by building the sales infrastructure needed to convert clinical success into hard dollars. 2. The "Razor and Blade" model begins to roll: IceCure operates on a business model where they sell both the machine (ProSense) and the disposable needles (probes) used for every freeze treatment. More salespeople in the field -> More installed machines -> A rapidly increasing and recurring sale of disposable needles with high margins. 3. The Risk: Increased "Burn Rate" in the short term When expanding its sales team, the company's operating costs (SG&A) immediately increase, while revenues from increased sales typically lag a bit (because the sales cycle in hospitals can take 3-9 months). As an investor, you should keep an eye on their cash reserves (they had approx. 8.1 million USD in cash at the end of Q1 2026) to ensure they have enough money to finance this growth phase without further diluting shareholders in the near future. Overall assessment: This is a classic "growth news". It confirms that there is real, organic demand in the US market for an alternative to traditional breast surgery (lumpectomy). It costs money to make money, and IceCure is now stepping on the gas in the USA to quickly gain market share. 🤞🤝
- ·25.6.Most things seem to point in the right direction, competent management, great potential for the product, analysts who are unequivocally positive and high price targets. These are shares at a cheap price now. There is also a high probability that the application in Japan will go through, as Terumo is responsible for the application.
- ·25.6. · MuokattuWhy is this important for IceCure? Retains large investors: Many investment funds and institutional investors have rules that they are not allowed to own shares that cost under 1 dollar, or shares that are traded on the unregulated "penny stock" markets. By remaining on Nasdaq, IceCure maintains access to the big money. Peace of mind: Management has now averted a potential crisis. Instead of having to spend energy on panic solutions (such as a reverse stock split, where shares are merged to artificially pump up the price), they can now focus 100% on their business – such as the upcoming approval process in Japan, which you read about in the other news. Sign of confidence: That the share price has climbed back above 1 dollar by its own strength often shows that the market and investors have gained greater faith in the company's future, potentially aided by good clinical news. Important! 🙏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 12.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 13.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
56 päivää sitten
‧33 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 18.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 12.8. | ||
2026 Q1 - tulosraportti 12.5. | ||
2025 Q4 - tulosraportti 17.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 13.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·11.9.Key points of the news Classification as Class III Medical Device: The approval applies to their ProSense cryoablation technology (and associated probes). Class III is the strictest category in China for devices used for life-sustaining or invasive procedures. What does the technology do? ProSense uses extreme cold (liquid nitrogen) to freeze and destroy tumors (both benign and cancerous) in e.g., breast, kidneys, lungs, and bones as a gentle alternative to traditional surgery. Opening up a giant market: China is an enormous market with hundreds of thousands of new cancer cases annually, and the approval officially opens the doors for the company to commercialize and sell their systems there (often via local distribution agreements, including with strong partners like Medtronic's local branches). Is it good or bad? This is clearly very good news for IceCure Medical for several reasons: Access to a massive market: China is one of the world's largest growth markets for health technology. Getting through the eye of the needle that the Chinese NMPA approval represents opens up enormous sales potential in the long term. Validation of the technology: Passing the eye of the needle to get a Class III approval serves as a seal of quality for the product's safety and effectiveness, which also strengthens the company's global position. Strained company needs growth: Like many other small biotech companies, IceCure has historically struggled with weak earnings and low stock prices. News of commercial expansion of this caliber is precisely the type of catalyst investors look for to boost revenue. All in all, a strategic feather in the cap for IceCure, moving them from pure development and approval phase into a real, global sales phase in one of the world's most important markets. https://finance.yahoo.com/healthcare/articles/icecure-secures-china-nmpa-approval-135700845.html
- ·14.7. · Muokattuhttps://finance.yahoo.com/healthcare/articles/icecure-expands-u-commercial-team-123200784.html The company has just announced a significant expansion of their US sales and marketing team. This comes as a direct response to an explosively growing demand for their flagship product, the ProSense® system, for the treatment of early-stage breast cancer. What is the background for the news? 70% growth in the USA: IceCure recently announced that their active commercial installed base in the USA has grown by a full 70%. This growth was triggered by them receiving crucial FDA approval in October 2025 to treat low-risk, early-stage breast cancer in women over 70 years old. Geographical expansion: To meet demand, the company has hired dedicated sales and marketing staff in key regions such as New York, Southern California, and the Midwest. ProSense procedures are now performed in major metropolitan areas like Los Angeles, Detroit, Dallas, and Atlanta. What does this mean for you as an investor? If you look at IceCure through investor glasses, there are three crucial things to take away from this expansion: 1. The company shifts gears from "development" to "commercial execution" For many years, IceCure has been a case about clinical studies (such as the large ICE-3 study) and waiting for FDA. Now the approval is in, and the company shows action by building the sales infrastructure needed to convert clinical success into hard dollars. 2. The "Razor and Blade" model begins to roll: IceCure operates on a business model where they sell both the machine (ProSense) and the disposable needles (probes) used for every freeze treatment. More salespeople in the field -> More installed machines -> A rapidly increasing and recurring sale of disposable needles with high margins. 3. The Risk: Increased "Burn Rate" in the short term When expanding its sales team, the company's operating costs (SG&A) immediately increase, while revenues from increased sales typically lag a bit (because the sales cycle in hospitals can take 3-9 months). As an investor, you should keep an eye on their cash reserves (they had approx. 8.1 million USD in cash at the end of Q1 2026) to ensure they have enough money to finance this growth phase without further diluting shareholders in the near future. Overall assessment: This is a classic "growth news". It confirms that there is real, organic demand in the US market for an alternative to traditional breast surgery (lumpectomy). It costs money to make money, and IceCure is now stepping on the gas in the USA to quickly gain market share. 🤞🤝
- ·25.6.Most things seem to point in the right direction, competent management, great potential for the product, analysts who are unequivocally positive and high price targets. These are shares at a cheap price now. There is also a high probability that the application in Japan will go through, as Terumo is responsible for the application.
- ·25.6. · MuokattuWhy is this important for IceCure? Retains large investors: Many investment funds and institutional investors have rules that they are not allowed to own shares that cost under 1 dollar, or shares that are traded on the unregulated "penny stock" markets. By remaining on Nasdaq, IceCure maintains access to the big money. Peace of mind: Management has now averted a potential crisis. Instead of having to spend energy on panic solutions (such as a reverse stock split, where shares are merged to artificially pump up the price), they can now focus 100% on their business – such as the upcoming approval process in Japan, which you read about in the other news. Sign of confidence: That the share price has climbed back above 1 dollar by its own strength often shows that the market and investors have gained greater faith in the company's future, potentially aided by good clinical news. Important! 🙏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt